A5068480776- Cancer Genomics and Diagnostics
- BRCA gene mutations in cancer
- Genomics and Rare Diseases
- Genetic factors in colorectal cancer
- Breast Cancer Treatment Studies
- Cancer, Lipids, and Metabolism
- Cancer Treatment and Pharmacology
- Cholesterol and Lipid Metabolism
- Molecular Biology Techniques and Applications
- Colorectal Cancer Treatments and Studies
- Estrogen and related hormone effects
- DNA Repair Mechanisms
- Statistical Methods in Clinical Trials
- Advanced Breast Cancer Therapies
- Synthesis of β-Lactam Compounds
- Lung Cancer Treatments and Mutations
- Phytochemical compounds biological activities
- Ferrocene Chemistry and Applications
- Genomic variations and chromosomal abnormalities
- PARP inhibition in cancer therapy
- Hepatocellular Carcinoma Treatment and Prognosis
- Hormonal Regulation and Hypertension
- Inflammatory mediators and NSAID effects
- Lung Cancer Research Studies
- Bioinformatics and Genomic Networks
Indiana University School of Medicine
2009-2024
Indiana University
2009-2024
Indiana University – Purdue University Indianapolis
2011-2024
University of Indianapolis
2010-2024
Indiana University Melvin and Bren Simon Comprehensive Cancer Center
2021-2024
Indiana University Health
2020-2022
University School
2021
Cofactor Genomics (United States)
2010
The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic focus primarily on assessment of pathogenic/likely pathogenic (P/LP) variants associated with increased risk breast, ovarian, pancreatic, prostate cancer, including BRCA1 , BRCA2 CDH1 PALB2 PTEN TP53 recommended approaches to genetic counseling/testing care strategies in individuals these P/LP variants. These Insights summarize important updates regarding: (1) a new section transgender, nonbinary...
Patients with triple-negative breast cancer (TNBC) residual disease after neoadjuvant chemotherapy (NAC) have high risk of recurrence prior data suggesting improved outcomes capecitabine. Targeted agents demonstrated activity across multiple types. BRE12-158 was a phase II, multicenter trial that randomly allocated patients TNBC NAC to genomically directed therapy versus treatment physician choice (TPC).From March 2014 December 2018, 193 were enrolled. Residual tumors sequenced using...
A germline pathogenic variant may be present even if the results of tumor genomic sequencing do not suggest one. There are key differences in assay design and reporting variants between somatic laboratories. When appropriate, both tests should completed to aid therapy decisions determining optimal screening risk-reduction interventions.
1000 Background: Neuropathy, one of the most common toxicities associated with taxane therapy, may be severe, function-limiting, and sometimes irreversible. Established predictors for increased risk include advanced age, diabetes, type/dose/schedule taxane. No established biomarkers have been identified to predict patients at greatest risk. Methods: E5103 is a randomized phase III trial comparing standard adjuvant chemotherapy early stage breast cancer same plus concurrent bevacizumab or...
Abstract Next-generation sequencing of circulating tumor DNA (ctDNA) is a non-invasive method to guide therapy selection for cancer patients. ctDNA variant allele frequency (VAF) commonly reported and may aid in discerning whether germline or somatic. We report on the fidelity VAF as predictor carriage. Two patient cohorts were studied. Cohort 1 included patients with known variants. 2 any detected by assay 40–60%. In cohort 1, 36 91 (40%) variants identified through analysis 39–87.6%. 2,...
Identification of incidental germline mutations in the context next-generation sequencing is an unintended consequence advancing technologies. These data are critical for family members to understand disease risks and take action.A retrospective cohort analysis was conducted 1,028 adult patients with metastatic cancer who were sequenced tumor whole exome (WES). Germline variant call files mined pathogenic/likely pathogenic (P/LP) variants using ClinVar database narrowed high-quality...
Abstract Purpose: This retrospective analysis aimed to determine the relationship between body mass index (BMI) and circulating tumor DNA (ctDNA) in triple-negative breast cancer (TNBC), evaluate impact of BMI on disease recurrence survival homogeneous, high-risk population patients with residual TNBC after neoadjuvant chemotherapy. Experimental Design: BRE12-158 was a phase II trial genomically directed therapy versus physician’s choice ctDNA isolated from plasma samples, categorized as...
The identification of cancer-predisposing germline variants has potentially substantial clinical impact for patients and their families. Although management guidelines have been proposed some genes, other genes are lacking. This review focuses on the current surveillance most common hereditary cancer syndromes discusses pivotal studies supporting available guidelines. We also highlight gaps in carriers, cascade testing at-risk relatives, challenges impeding proper follow-up optimal...
e21017 Background: The anti-VEGF antibody, bevacizumab, has been FDA approved for the treatment of breast cancer. While germline variability (i.e. single nucleotide polymorphisms) may serve as a predictive marker therapy, to date tumor-specific not. More specifically, amplification or deletion VEGFA gene not studied evaluated prognostic biomarker Methods: A VEGFA/centromere enumerization-6 (CEN-6) probe was created and validated using DNA clones restriction enzyme fragment measurements....
e13541 Oxysterols are oxygenated derivatives of cholesterol. They have nuclear receptors and been shown to pass cell membranes the blood-brain barrier at a faster rate than cholesterol itself. In addition, oxysterols ascribed number important roles in connection with turnover, atherosclerosis, apoptosis, necrosis. antitumor effects on experimental models. These compounds however may be toxic our knowledge, although some tested animals, none reached clinical level. 24-ethyl-cholestane-...
Abstract Introduction: Bevacizumab is a beneficial therapy in several advanced cancer types. Predictive biomarkers to better understand which patients are destined benefit or experience toxicity needed. Associations between bevacizumab induced hypertension and survival have been reported but with conflicting conclusions. Methods: We performed post-hoc analyses evaluate the association 3,124 from two phase III adjuvant breast trials, E5103 BEATRICE. Differences invasive disease-free (IDFS)...
Multigene panel testing has allowed for the detection of a growing number inherited pathogenic/likely pathogenic variants in people at high risk cancer, including endometrial cancer (EC). Hereditary syndromes associated with EC include Lynch syndrome, PTEN hamartoma tumor and Peutz-Jeghers syndrome. This manuscript provides latest recommendations from NCCN Guidelines Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, Gastric on screening management patients these syndromes, as...
Abstract Background: Triple-negative breast cancer (TNBC) has been plagued by the absence of targeted therapies. Discovery therapeutic targets in TNBC part, hampered an inadequate understanding transcriptional biology normal as optimal comparator. Using next-generation sequencing, we embarked on a study to compare transcriptomes and comprehensively identify novel analyzing all full length transcripts expressed these tissues. Methods: Normal tissues from healthy pre-menopausal volunteers with...
Abstract Our group has previously reported that SNPs in the VEGF promoter are strongly associated with efficacy and toxicity to anti-VEGF antibody bevacizumab metastatic breast cancer. In order better understand biologic mechanism for our biomarkers, we embarked on a comprehensive evaluation of genetic variation coupled study its intrinsic function. By resequencing 96 DNA samples (48 Caucasians, 48 African-Americans) promoter, elucidated complete haplotype structure identified were not prior...
Abstract Background: Neoadjuvant chemotherapy (NAC) is a standard approach for many patients with triple negative breast cancer (TNBC). Our group, and others, have previously reported that the detection of circulating tumor DNA (ctDNA) after NAC surgery surrogate presence minimal residual disease (MRD) leading to inferior survival outcomes. Further, our group has also emergence somatic TP53 mutations in tissue samples post-NAC was associated In this study, we sought determine whether...
Abstract Next-generation sequencing (NGS) of circulating tumor DNA (ctDNA) is a non-invasive method to guide therapy selection for cancer patients. ctDNA variant allele frequency (VAF) commonly reported and may aid in discerning whether germline or somatic. We report on the fidelity VAF as predictor carriage. Two patient cohorts were studied. Cohort 1 included patients with known variants. 2 any detected by assay 40–60%. In cohort 1, 36 91 (40%) variants identified through analysis 39-87.6%....